Literature DB >> 8543073

Prevention of immune-mediated corneal graft destruction with the anti-lymphocyte monoclonal antibody, CAMPATH-1H.

D K Newman1, J D Isaacs, P G Watson, P A Meyer, G Hale, H Waldmann.   

Abstract

We report a patient with peripheral rheumatoid corneal melting who developed a corneal perforation in one eye requiring tectonic keratoplasty. Nine consecutive corneal grafts were rapidly destroyed despite systemic immunosuppression with corticosteroid, cyclophosphamide, azathioprine and cyclosporin A. A rejection episode was observed in one graft before it melted and allograft rejection may have contributed to the destruction of other grafts. Corneal graft survival was ultimately achieved by systemic immunosuppression with the anti-lymphocyte monoclonal antibody, CAMPATH-1H. A single episode of rejection developed in the early post-operative period which was easily reversed by topical corticosteroid. Corneal melting has not recurred and the graft has now remained intact and clear for 24 months. Anti-lymphocyte monoclonal antibodies may therefore provide effective immunosuppression in the treatment of refractory ocular disorders.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8543073     DOI: 10.1038/eye.1995.140

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  10 in total

Review 1.  Immunomodulation of autoimmune responses with monoclonal antibodies and immunoadhesins: treatment of ocular inflammatory disease in the next millennium.

Authors:  A D Dick; J D Isaacs
Journal:  Br J Ophthalmol       Date:  1999-11       Impact factor: 4.638

Review 2.  [Immunomodulation in penetrating keratoplasty. Current status and perspectives].

Authors:  U Pleyer
Journal:  Ophthalmologe       Date:  2003-12       Impact factor: 1.059

3.  Mooren's ulcer resolved with campath-1H.

Authors:  J van der Hoek; A Azuara-Blanco; K Greiner; J V Forrester
Journal:  Br J Ophthalmol       Date:  2003-07       Impact factor: 4.638

4.  Subconjunctival injection of in vitro transforming growth factor-β-induced regulatory T cells prolongs allogeneic corneal graft survival in mice.

Authors:  Qing Xu; Xiaobo Tan; Yingnan Zhang; Ying Jie; Zhiqiang Pan
Journal:  Int J Clin Exp Med       Date:  2015-11-15

Review 5.  Short term immunosuppressive therapy and long-term immunoregulation: promises and problems.

Authors:  J Isaacs; A Dick
Journal:  Br J Ophthalmol       Date:  1996-12       Impact factor: 4.638

6.  Campath-1H therapy in refractory ocular inflammatory disease.

Authors:  A D Dick; P Meyer; T James; J V Forrester; G Hale; H Waldmann; J D Isaacs
Journal:  Br J Ophthalmol       Date:  2000-01       Impact factor: 4.638

7.  Use of Post-transplant Cyclophosphamide Treatment to Build a Tolerance Platform to Prevent Liquid and Solid Organ Allograft Rejection.

Authors:  Casey O Lightbourn; Dietlinde Wolf; Sabrina N Copsel; Ying Wang; Brent J Pfeiffer; Henry Barreras; Cameron S Bader; Krishna V Komanduri; Victor L Perez; Robert B Levy
Journal:  Front Immunol       Date:  2021-03-02       Impact factor: 7.561

8.  Prevention of corneal allograft rejection in a mouse model of high risk recipients.

Authors:  A Vítová; M Filipec; A Zajícová; M Krulová; V Holán
Journal:  Br J Ophthalmol       Date:  2004-10       Impact factor: 4.638

Review 9.  Alemtuzumab therapy for multiple sclerosis.

Authors:  Alasdair J Coles
Journal:  Neurotherapeutics       Date:  2013-01       Impact factor: 7.620

Review 10.  Rapid deterioration of Mooren's ulcers after conjunctival flap: a review of 2 cases.

Authors:  Saiqun Li; Yuqing Deng; Caiyuan Du; Haixiang Huang; Jing Zhong; Ling Chen; Bowen Wang; Jin Yuan
Journal:  BMC Ophthalmol       Date:  2017-06-15       Impact factor: 2.209

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.